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Abstract
Despite the large amount of human and experimental studies no effective (prophylactic)
treatment exists for chemotherapy induced peripheral neuropathy (CIPN), a disabling side
effect of many cancer treatments. One of the underlying reasons for this could be that often
the preclinical animal models used are not the best representation of the clinical situation.
We therefore present a systematic summary and comparison of all animal models currently
described in literature for CIPN focusing on stimulus evoked pain-like behaviour and neuro-
physiological alterations in nerve function (650 included papers, and a comparison of 183
models), that resulted in a clear overview of the most effective and robust CIPN models
using an administration route used in clinical practice. Using our three-step approach (step
1: efficacy; step; 2 robustness and step 3: mimicking the clinical situation) we show that all
mice CIPN models treated with either paclitaxel or cisplatin using an administration route
used in clinical practice seem suitable models. Three specific models using paclitaxel or cis-
platin that stand out are 1) C57BL/6 female mice receiving paclitaxel and 2) CD1 male mice
receiving paclitaxel and 3) C57BL/6 male mice receiving cisplatin. This overview may help
scientists selecting suitable CIPN models for their research. We hypothesize that by using
effective and robust animal models that mimic the clinical situation as much as possible, the
translational value of preclinical study results with respect to the potential of identifying
promising treatments for CIPN in the future, will prove. The methodology described in this
paper, aimed at comparing animal models, is novel and can be used by scientist in other
research fields as well.
Introduction
Over the last decades, there has been a remarkable increase in the long-term survival rate in
cancer patients due to improvement in early detection, precise subtype characterization and
development of new treatment options [1, 2], An emerging issue in cancer treatment is dealing
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with long-term sequelae that impair quality of life in cancer patients and survivors [3, 4]. One
of the most common reported symptoms derived from cancer treatment is chemotherapy
induced peripheral neuropathy (CIPN), which is caused by differential damage to peripheral
nervous system depending on the administered neurotoxic antineoplastic agent, such as tax-
anes, platinum compounds, vinca alkaloids, epothilones, protease inhibitors and thalidomide
[5, 6]. It mainly presents as a dose-dependent sensory length-dependent neuropathy with
symptoms including numbness, paresthesias, loss of proprioception and hyperalgesia; less
often patients will present with motor weakness and autonomic changes [7, 8].
The incidence of CIPN varies between type and dose of chemotherapeutic agents, method
of assessment [9] and period after cessation of chemotherapy [10–12]. At 6 months roughly
30% up to 71% of patients continue to suffer from CIPN [9, 13]. Some patient groups with
neuropathy at baseline, older age, genetic varieties or prior exposure to neurotoxic agents are
more at risk for developing CIPN [13, 14]. Neuropathic symptoms may lead to dose reduction
or early cessation of chemotherapy, thereby potentially impacting patient survival. Despite the
large amount of human and experimental studies, until now no effective prophylactic treat-
ment exists [15–17], treatment of CIPN related pain remains difficult [5, 15, 16, 18] and
reduces quality of life of cancer patients and survivors [19].
One of the underlying reasons for this could be the fact that often not all laboratory work
done in animals hasn’t been evaluated before deciding to apply it to patients. As a conse-
quence, specific treatment options might be either discarded for testing in humans or are erro-
neously selected resulting in a mismatch between preclinical and clinical benefit. In addition,
the animal models and experimental design used in the preclinical phase may not be the best
representation of the clinical situation possibly leading to translational failure. In case of CIPN
for example, often doses and mode of deliveries of the chemotherapeutic agents are used that
may not representative of the clinical situation, and many preclinical studies do not seem to be
adequately randomised and blinded.
To identify possible treatment strategies for CIPN, in either the already published literature
or by conducting new animal studies, it is urgent to identify and compare the efficacy and rele-
vance to the clinical situation of all CIPN animal models used in literature so far and select the
most promising ones.
Therefore, we conducted a systematic review of all animal studies published so far in the
field of CIPN and developed a strategy to compare the resulting animal models.
Results
Study selection
Fig 1 shows that the electronic search strategy retrieved 5,847 records from PubMed and 8,164
articles from EMBASE. Out of 12,412 unique references, 809 papers were included after
screening of the title and abstracts. Out of these 809 papers, 650 met our predefined inclusion
criteria. The references of the included studies can be found in S1 File.
Study characteristics
Based on the species, strain, sex and type of chemotherapy used, the various CIPN models
used in literature were identified. A total of 183 unique CIPN models were identified (S1
Table). The number of times that the models were used in these 650 included papers was also
counted and resulted in 1,023 comparisons.
Animal characteristics. In these 183 different models, twelve different species were used.
85.2% of the models conducted experiments in rodents (92 in mice and 64 in rat) and 14.8%
were conducted in other species: guinea pigs (n = 6); cats (n = 4); chickens (n = 3), cynomolgus
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Fig 1. Flowchart diagram.
https://doi.org/10.1371/journal.pone.0221787.g001
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monkey (n = 3), rhesus monkey (n = 1), rabbits (n = 3), drosophila melanogaster (n = 3), dogs
(n = 2), catfish (n = 1) and zebrafish (n = 1). Forty different strains amongst the different spe-
cies have been used.
Data were predominantly obtained from male animals (697 (68%) out of 1023 compari-
sons). Regarding the 183 different models, 69 (37.7%) models used male animals. Females
were used in 45 models (24.6%), and 34 (18.6%) models used mixed sex groups. Unfortunately
in 35 (19.1%) models the sex was not described.
Chemotherapy characteristics. Twenty seven different types of chemotherapy had been
used among these 183 models: 1) 28.4% of the models used a platinum based chemotherapy
(e.g. cisplatin (n = 29), oxaliplatin (n = 20), carboplatin (n = 1), lipoplatin (n = 1) and ormapla-
tin (n = 1)); 2) 28.4% of the models used taxanes (e.g. paclitaxel (n = 46), docetaxel (n = 5) and
nab-paclitaxel (n = 1)); 3) 26.8% of the models used a vinca-alkaloid based chemotherapy (vin-
cristine (n = 38), vinblastine (n = 6), vindesine (n = 4) and vinorelbine (n = 1)) and 4) 16.4% of
the models used another type of chemotherapy (e.g. bortezomib (n = 10), methotrexate
(n = 1), etoposide (n = 1), thalidomide (n = 2), ethoglucid (n = 1), epothilone-B (n = 1), eribu-
lin (n = 1), gemcitabine (n = 2), ixabepilone (n = 1), quelamycin (n = 1), sorafenib (n = 1), sur-
amin (n = 1), doxorubicin (n = 4), salinomycin (n = 1) and tamoxifen (n = 2)).
Route of administration. Also the route of administration varied greatly across and
within the models (e.g. a CIPN animal model was initially defined based on species, strain, sex
and type of chemotherapy used, thus within a model the same chemotherapeutic agent could
be administered in various ways).
In order to analyse the variation in administration route we added route of administration
as a factor in the specification of the various CIPN models used in literature. This resulted in
222 different CIPN models.
Seven different routes of administration had been used: intraperitoneal (59.5%), intrave-
nous (27.5%), subcutaneous (6,3%), oral (1,8%), intramuscular (0,5%), intradermal (0,5%),
and intraventricular (0,5%). In 3,6% of the models failed to report the route of administration
and hence were classified as unknown.
Polyneuropathy characteristics. In order to assess later in this review whether or not a
model caused CIPN we extracted and analysed whether or not a study measured one of the fol-
lowing outcomes: mechanical allodynia, thermal hyper and hypoalgesia, motor function and/
or electrophysiological measurements and histological damage to the peripheral nervous
system.
Overall 28.430% (n = 52) models used only one of the above-mentioned outcomes to assess
CIPN. The other 71.6% assessed two or more outcomes. 34.4% (n = 63) used two tests, 12.6%
(n = 23) used three tests, 13.1% (n = 24) used four tests and 11.5% (n = 21) used all five tests.
Step 1: Efficacy of the CIPN models
In order to assess how effective the CIPN models used in literature are in causing polyneuropa-
thy the efficacy of each model was calculated (% of CIPN on two of our (peripheral) poly-
neuropathy outcomes), and subsequently the animal models with promising efficacy based on
the following criteria: 1) the animal model should at least have been tested five times; 2) the
animal model causes significant (peripheral) polyneuropathy in at least 90% of the experiments
in two or more outcomes, were selected, and tabulated.
S1 Table provides an overview of the efficacy of CIPN models ranked by animal species.
S2 Table provides an overview of the efficacy of CIPN models ranked by type of chemother-
apy used.
Identifying effective, robust and relevant models for CIPN
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S3 Table provides a summary of the efficacy of the models that might be promising, as they
scored significant (peripheral) polyneuropathy in at least 90% of the experiments in two or
more outcomes but did not reach our reproducibility limit (n = 5).
The Big Five models based on efficacy. This above-mentioned analyses resulted in five
promising models (Table 1). Rodents were used in all of these models (rats 60%, mice 40%).
Two models used taxane (paclitaxel n = 2), two models used a platinum-based chemotherapy
(cisplatin n = 1, oxaliplatin n = 1) and one model used a vinca-alkaloid (vincristine n = 1).
Three models showed in 100% of the studies polyneuropathy (in at least two out of our five
outcomes) after chemotherapy (Table 1).
Rats Wistar, both sexes, receiving vincristine
A total of ten experiments used this model. All experiments showed significant polyneuro-
pathy (100%) in at least two outcomes for polyneuropathy. All five predefined outcomes for
polyneuropathy have been studied in this model and they all showed in all comparisons signifi-
cant polyneuropathy. In this model all tests have been conducted e.g. thermal hyper and
hypoalgesia (n = 10 (100%)), mechanical allodynia (n = 10 (100%)), histological damage to the
peripheral nervous system (n = 5 (83%)), sensory-motor coordination impairment (n = 2
(100%)) and electrophysiological impairments (n = 1 (100%)). All experiments administered
vincristine intraperitoneally (100%). The cumulative dosage of vincristine ranged from 0,5
mg/kg (n = 7) up to 1 mg/kg (n = 2), with in between 0,75 mg/kg (n = 1).
Mice CD1, male, receiving paclitaxel
A total of nine experiments used this CIPN model, whereof a total of six experiments mea-
sured polyneuropathy in at least two outcomes. All experiments showed significant polyneuro-
pathy (100%). The age of the mice ranged from 4 to 52 weeks. In a two experiments age was
not reported. The cumulative dosage ranged from 8 mg/kg (n = 2) up to 126,6 mg (n = 1), with
in between 10 mg/kg (n = 5) and 16 mg/kg (n = 1). Route of administration was intraperito-
neal in eight experiments (89%) and subcutaneous in one experiment (11%).
Four of our predefined outcomes have been assessed in this model e.g. assessment of histo-
logical damage to the peripheral nervous system (n = 4 (100%)), electrophysiological impair-
ments (n = 1 (100%)), thermal hyper or hypoalgesia (n = 7 (100%)) and mechanical allodynia
(n = 7 (100%)). Sensory-motor coordination tests were not conducted in this model.
Mice C57BL/6, female, receiving paclitaxel
A total of thirteen experiments have reportedly been performed, whereof a total of eight
experiments measured polyneuropathy in at least two outcomes. All thirteen experiments
showed significant polyneuropathy (100%)
Table 1. Overview of the “Big Five”–most effective animal models of chemotherapy-induced polyneuropathy, defined by species, strain, chemotherapy and sex.
Species Strain Chemotherapy Sex n_1 CIPN_1 (%) n_>1 CIPN_>1 (%)
rats Wistar vincristine both 10 100% 10 100%
mice CD1 paclitaxel male 9 100% 6 100%
mice C57BL/6 paclitaxel female 13 100% 8 100%
rats Wistar cisplatin female 34 94% 18 94%
rats Sprague Dawley oxaliplatin male 104 100% 62 92%
Most effective animal models of chemotherapy-induced polyneuropathy based on calculating the efficacy of each model in causing polyneuropathy. CIPN model are
defined by species, strain, chemotherapy and sex. n: number of experiments using a specific model. _1: chemotherapy-induced polyneuropathy in one of the predefined
outcomes. _>1: chemotherapy-induced polyneuropathy in more than one of the predefined outcomes (e.g. mechanical allodynia, thermal hyper and hypoalgesia,
sensory-motor coordination, electrophysiological measurements and/or histological damage to the peripheral nervous system
https://doi.org/10.1371/journal.pone.0221787.t001
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The age of the mice ranged from 5 weeks up to adulthood. In six experiments age was not
reported. Cumulative dosage ranged from 4 mg/kg (n = 1) up to 180 mg/kg (n = 3), with in
between 8 mg/kg (n = 1), 16 mg/kg (n = 2), 18 mg/kg (n = 2), 32 mg/kg (n = 3) and 70 mg/kg
(n = 1). Route of administration was intraperitoneal in ten experiments (77%) and intravenous
in three experiments (23%).
In this model all predefined outcomes have been assessed e.g. histological damage to the
peripheral nervous system (n = 4 (100%)), electrophysiological measurements (n = 3 (100%)),
thermal hyper and hypoalgesia (n = 6 (100%)), sensory-motor coordination impairment (n = 4
(80%)) and mechanical allodynia (n = 7 (100%)).
Rats Wistar, female, receiving cisplatin
A total of thirty-seven experiments have used this model. Nineteen experiments measured
polyneuropathy in at least two outcomes. Ninety-five percent of the comparisons showed sig-
nificant polyneuropathy. All 5 predefined outcomes were assessed. In 95% of the comparisons
that studied histological damage to the peripheral nervous system significant damage was
observed. Electrophysiological impairment and mechanical allodynia were observed in all
comparisons (electrophysiological testing n = 27, and mechanical allodynia n = 2). Seventy
five percent of the experiments showed significant thermal hyper and hypoalgesia (n = 3) or
sensory motor impairment (n = 3).
The age of the mice ranged from 8 weeks up to 13 weeks. In eighteen experiments age was
not reported. Cumulative dosage ranged from 0,0528 mg/kg (n = 1) up to 32 mg/kg (n = 2),
with in between 4 mg/kg (n = 1), 7 mg/kg (n = 3), 9 mg/kg (n = 1), 12 mg/kg (n = 1), 15 mg/kg
(n = 1), 16 mg/kg (n = 8), 18 mg/kg (n = 8), 20 mg/kg (n = 5), 22 mg/kg (n = 2), 23 mg/kg
(n = 1) and 5 mg (n = 1).
In 36 experiments (97%) the route of administration was intraperitoneal. Only one study
(3% administered cisplatin intravenously.
Rats Sprague Dawley, male, receiving oxaliplatin
A total of 104 experiments used this model. Sixty-two experiments measured polyneuropa-
thy in at least two outcomes. In 92% of the comparisons significant polyneuropathy was
observed (92%). All predefined outcomes were assessed. Mechanical allodynia was predomi-
nantly studied (n = 89 (100%)). Significant thermal hyper and hypoalgesia was observed in
90% of the comparisons (n = 68). Histological damage to the peripheral nervous system and
electrophysiological impairment was observed in all comparisons (histological damage n = 24;
electrophysiological damage n = 8). Eight out of 24 experiments showed sensory motor
impairment.
The age of the mice ranged from 5 weeks up to adulthood. In sixty-nine experiments age
was not reported. Cumulative dosage ranged from 0,002 mg/kg (n = 1) up to 90 mg/kg (n = 1),
with in between 0,004 mg/kg (n = 1), 0,01 mg/kg (n = 1), 0,02 mg/kg (n = 1), 0,5mg/kg (n = 1),
1 mg/kg (n = 1), 2 mg/kg (n = 5), 3 mg/kg (n = 1), 4 mg/kg (n = 2), 5 mg/kg (n = 1), 6 mg/kg
(n = 17), 8 mg/kg (n = 7), 9 mg/kg (n = 1), 10 mg/kg (n = 8), 12mg/kg (n = 1), 15mg/kg
(n = 1), 16 mg/kg (n = 4), 18mg/kg (n = 3), 19,2 mg/kg (n = 1), 20mg/kg (n = 2), 21mg/kg
(n = 1), 24 mg/kg (n = 4), 30mg/kg (n = 1), 32 mg/kg (n = 15), 36 mg/kg (n = 18), 50,4 mg/kg
(n = 1), 64 mg/kg (n = 1) and 72 mg/kg (n = 1). Route of administration was intraperitoneal in
85 experiments (82%), intravenous in fifteen experiments (14%) and intradermal in four
experiments (4%).
Step 2: Robustness of the CIPN models
In order to assess the robustness of our “big five” models, the data set was reanalysed using dif-
ferent categories to specify the various CIPN models used (e.g. strain and/or sex included in
Identifying effective, robust and relevant models for CIPN
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the specification of CIPN models). Our analysis showed that three of our five initially selected
models appear either in all four or in at least three analyses as most effective models. These
three models are:
1. Mice C57BL/6, female, receiving paclitaxel; appeared as effective model in 4 out of 4 analy-
ses using different categories to define CIPN models.
2. Mice CD1, male, receiving paclitaxel; appeared as effective model in 4 out of 4 analyses with
using different categories to define CIPN models.
3. Rats Sprague Dawley, male, receiving oxaliplatin; appeared as effective model in three out
of four analyses using different categories to define CIPN models (Table 2), indicating that
this model appears robust across sex, but not very robust across strains (e.g. not reaching
the 90% significance level for peripheral neuropathy in 2 or more outcomes).
However, it is important to realize that the number of variations in models used within a
category and the amount of available evidence per model largely influences our results. For
example, the rat model receiving oxaliplatin (effective model in three out of four analyses
using different categories to define CIPN models) appears not so robust across strains (the
model did not appear as effective in the analyses using solely, species, chemotherapy and sex to
define a CIPN model), and robust across sex of the animals used. However, when taking into
account the variations in models within a category, it becomes clear that oxaliplatin was solely
tested in males. Therefore, we can’t draw any conclusions on the robustness of this model
regarding sex of the animals used. Thus, based on the poor robustness across strains and
Table 2. Overview of the efficacy and number of comparisons per model of CIPN models ranked animal species.
Species Strain Chemotherapy Sex n CIPN
species, strain,
chemotherapy, sex
Mice C57BL/6 Paclitaxel Female 8 8 (100%) 4
Mice CD1 Paclitaxel Male 6 6 (100%) 4
Rats SD Oxaliplatin Male 62 57 (92%) 3
Rats Wistar Cisplatin Female 19 18 (95%) 1
Rats Wistar Vincristine Both 10 10 (100%) 2
species, chemotherapy, sex Mice - Paclitaxel Male 33 30 (91%) 4
Mice - Paclitaxel Female 21 19 (90%) 4
Mice - Paclitaxel Both 5 5 (100%) 2
species, strain,
chemotherapy
Mice CD1 Paclitaxel - 10 10 (100%) 4
Mice C57BL/6 Paclitaxel - 30 28 (93%) 4
Rats Wistar Vincristine - 15 15 (100%) 2
Rats SD Oxaliplatin - 63 58 (92%) 3
species,
chemotherapy
Mice - Bortezomib - 10 9 (90%) 1
Mice - Cisplatin - 29 26 (90%) 1
Mice - Paclitaxel - 64 58 (91%) 4
4
2
Rats - Oxaliplatin - 86 77 (90%) 3
n: number of experiments using a specific model. CIPN: number of experiments using a specific model for chemotherapy induced peripheral neuropathy showing
efficacy in more than one of the predefined outcomes (e.g. mechanical allodynia, thermal hyper and hypoalgesia, sensory-motor coordination, electrophysiological
measurements and/or histological damage to the peripheral nervous system). The colour code in the last column indicates how often a model appeared as an effective
model when using different categories to define CIPN models. Abbreviations: Sprague Dawley (SD)
https://doi.org/10.1371/journal.pone.0221787.t002
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unclear robustness across sex this model is no longer considered one of the most suitable ani-
mal models to study CIPN.
Paclitaxel was tested in nineteen strains of mice. As shown in Table 2 paclitaxel causes sig-
nificant (peripheral) polyneuropathy in 91% of the experiments using males, and 90% using
females.
In 4 strains of mice was paclitaxel tested in both male and female groups separately (e.g.
CD1, C57Bl6, AJ and Balb C mice).
Thus, mice CIPN models treated with paclitaxel show efficacy across various strains and
sex of the animals used.
Step 3: Mimicking the clinical situation
To conclude which of the existing CIPN models are most suitable for studying CIPN, not only
efficacy and robustness should be taken into account, but the models should also mimic the
clinical situation as close as possible. In a subsequent analysis we therefore excluded all models
that used administration routes that were not used or contraindicated in clinical practice
according to the British Columbia Cancer guidelines.
Nineteen types of administration routes, in total 166 comparisons (16% of the total number
of comparisons initially included) were excluded. Bortezomib I.P. (n = 28), Cisplatin S.C.
(n = 5), Docetaxel I.P. (n = 1), Gemicitabine I.P. (n = 2) Ormaplatin I.P. (n = 1), Oxaliplatin I.
D. (n = 4 and S.C. (n = 5), Paclitaxel S.C. (n = 3), Sorafenib I.V. (n = 1), Suramin I.P. (n = 2),
Tamoxifen I.P. (n = 1), Thalidomide I.P. (n = 3) and I.V. (n = 1), Vincristine I.M. (n = 1) and
I.P. (n = 104) and S.C. (n = 1) and intraventricular (n = 2), Vindesine S.C. (n = 1).
Re-analyses of step1 (efficacy) of all CIPN models using an administration route of chemo-
therapeutics that is currently used in clinical practice resulted in 4 of the same models as in the
previous analyses (Table 3). Instead of the “Rats Wistar, female, receiving cisplatin” one new
model popped up “mice C57BL6, male, receiving cisplatin”.
The robustness analyses (step 2) revealed that three out of the five selected models appear in
all four analyses.
1. mice C57BL/6, female, receiving paclitaxel
2. mice CD1, male, receiving paclitaxel
3. mice C57BL/6, male, receiving cisplatin
Two of those models were identified previously as well (1 and 2).
Cisplatin was tested in 8 strains. Cisplatin was tested in C57Bl6 males, females and mixed
groups and showed an efficacy of 100%. The remark however should be made that in females,
in mixed sex, and unknown sex groups, only one experiment was conducted per group.
Thus, mice CIPN models using administration routes used in clinical practice treated with
either cisplatin or paclitaxel show efficacy across various strains and sex of the animals used.
Sensitivity analyses
In our analyses a model could only be selected as a promising and suitable model in case a
model caused significant peripheral neuropathy in at least 90% of the experiments in 2 or
more outcomes. In the sensitivity analyses we changed this level to 85% and re-analysed step 1
(efficacy), step 2 (robustness) and step 3 (mimicking the clinical situation) and showed besides
the already identified 3 models using the data presented in S1 Table
1. Mice C57BL/6, female, receiving paclitaxel
Identifying effective, robust and relevant models for CIPN
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2. Mice CD1, male, receiving paclitaxel
3. Mice C57BL/6, male, receiving cisplatin one other promising model:
4. Mice C57BL/6, male, receiving paclitaxel
Initially also a second new model appeared; Mice C57BL/6, male, receiving oxaliplatin,
however, this model was solely tested in males and it can therefore not be concluded that this
model was robust across sex.
Study quality: Reporting of Blinding, randomization and sample size
calculation
In order to obtain a rough overview of the study quality of the 650 included papers we assessed
whether the papers reported the presence of any sample size or power calculations or any mea-
sures taken to blind the investigators or randomize the allocation of the animals. Out of our
650 included manuscripts 44% reported measures for blinding, 36% reported a measure for
randomisation and only 3% of the included papers reported sample size or power calculations.
In this score we also included the articles that explicitly mentioned that they did not conduct
blinding, randomisation or sample size calculations (S4 Table).
Discussion
We conducted a comprehensive summary (in the form of a systematic review) and compari-
son of all animal models currently described in literature for CIPN, that resulted in a clear
overview of all effective and robust models for CIPN focusing on stimulus evoked pain-like
Table 3. Overview of the efficacy and number of comparisons per model of CIPN models ranked animal species after excluding all models that used administration
routes that are not used in clinical practice.
Species Strain Chemotherapy Sex n CIPN
Species, strain, chemotherapy, sex Mice C57BL/6 Cisplatin Male 13 12 (92%) 4
Mice C57BL/6 Paclitaxel Female 8 8 (100%) 4
Mice CD1 Paclitaxel Male 6 6 (100%) 4
Rats SD Oxaliplatin Male 62 57 (92%) 3
Rats Wistar Cisplatin Female 19 18 (95%) 1
Species, sex, chemotherapy Mice Cisplatin Male 18 17 (94%) 4
Mice Paclitaxel Male 33 30 (91%) 4
Mice Paclitaxel Female 21 19 (90%) 4
Mice Paclitaxel Both 5 5 (100%) 2
Species, strain, chemotherapy Mice C57BL/6 Cisplatin 16 15 (94%) 4
Mice CD1 Paclitaxel 10 10 (100%) 4
Mice C57BL/6 Paclitaxel 30 28 (93%) 4
Rats SD Oxaliplatin 63 58 (92%) 3
Species, chemotherapy Mice Cisplatin 28 26 (93%) 4
Mice Paclitaxel 64 58 (91%) 4 2
Rats Oxaliplatin 86 77 (90%) 3
n: number of experiments using a specific model. CIPN: number of experiments using a specific model for chemotherapy induced peripheral neuropathy showing
efficacy in more than one of the predefined outcomes (e.g. mechanical allodynia, thermal hyper and hypoalgesia, sensory-motor coordination, electrophysiological
measurements and/or histological damage to the peripheral nervous system). The colour code in the last column indicates how often a model appeared as an effective
model when using different categories to define a CIPN model. Abbreviations: Sprague Dawley (SD)
https://doi.org/10.1371/journal.pone.0221787.t003
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behaviour and neurophysiological alterations in nerve function with an administration route
used in clinical practice.
In this systematic review 650 papers were included, resulting in 183 unique CIPN models
(based on species, strain, sex and type of chemotherapy used), and 1,023 independent compar-
isons. Twelve different species and 27 different types of chemotherapy were used in these
models.
Five outcome measures to identify the presence of CIPN were assessed: mechanical allody-
nia, thermal hyper and hypoalgesia, motor function, histological damage to the peripheral ner-
vous system and changes in electrophysiological measurements such as changes in nerve
conduction.
Using our three-step approach (efficacy, robustness and mimicking the clinical situation)
we show in this systematic review that all mice CIPN models treated with either paclitaxel or
cisplatin using an administration route used in clinical practice seem suitable models. Three
specific models using paclitaxel or cisplatin that stand out (based on the finding that thy are
reproduced at least five times and significant (peripheral) polyneuropathy in at least 90% of
the experiments in two or more outcomes), are
1. C57BL/6 female mice receiving paclitaxel and
2. CD1 male mice receiving paclitaxel and
3. C57BL/6 male mice receiving cisplatin.
Our review also provides a list of models that show high efficacy but have not been repro-
duced enough times to be included in our analyses but might be promising CIPN models in
the future. Last but not least, this review also provides an overview of the efficacy of CIPN
models ordered by type of chemotherapy.
A major strength of this paper, in addition to the large evidence base, is that it is the first
systematic review comparing the efficacy and relevance of all CIPN models published in
PubMed and Embase. Our overview can help scientists to select a suitable CIPN model for
their research. Using a suitable model, will probably lead to a higher translational value of pre-
clinical study results with respect to the potential of identifying promising treatments for
CIPN. Scientists need to be aware of the various available models, and how they differ in char-
acteristics and efficacy in causing CIPN. Our review fills this gap as the differences between
the various CIPN models are analysed and efficacy and internal, external and construct validity
issues are taken into account. For example, a suitable model needs to mimic clinical CIPN (e.g.
construct validity) as much as possible. By using administration routes, animal characteristics
and outcomes that poorly match the clinical situation for example, construct validity can be
threatened. We therefore analysed our entire dataset also without all models using administra-
tion route that that are not used in the clinical situation and show that in 16% of the compari-
sons initially included in this review administration routes are used that are not used or are
contraindicated in clinical practice. In addition, we included sex of the animals in our robust-
ness analyses because in human patients there is as far as we know, no clear evidence for a dif-
ference between males and females in CIPN rate and severity. Further, because all individual
CIPN outcomes have their shortcoming [20] we decided to label a study “effective” only in
case at least two outcomes related to on stimulus evoked pain-like behaviour and/ or neuro-
physiological alterations in nerve function are scored significant peripheral neuropathy. In this
systematic review we focused on 3 outcomes related to clinical symptoms (motor impairment,
thermal hyper and hypoalgesia and mechanical allodynia) and 2 related to clinical pathophysi-
ology (neuronal damage identified by either histological damage in the peripheral nervous sys-
tem or electrophysiological measurements).
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However, it is important to realize that no animal model will represents the full clinical situ-
ation perfectly (because of evolution determined species differences and by inevitable dissimi-
larities between the conditions created in animals and the human disorders being researched
[21]) and research findings therefore need to be confirmed in multiple animal models (as com-
parable results in multiple similar animal models would increase our confidence in the results
and applicability for the clinical situation).
Nevertheless, the results presented in this systematic review seem to be largely in line with
the clinical situation. We show that mice CIPN models treated with either paclitaxel or cis-
platin show high efficacy in causing CIPN (also across sex and various strains used), and this is
in concordance with the results from a recent meta-analysis of clinical studies showing high
prevalence of CIPN for both oxaliplatin (72%) and cisplatin (42%) as well [13]. Also, the results
from a recent multi-country multisite prospective longitudinal observational study shows that
especially paclitaxel is a chemotherapeutic causing one of the highest CIPN rates in patients
[9].
Limitations
This review has some important limitations. Firstly, we summarize and compare animal mod-
els for CIPN based on outcome measures related to allodynia/ hyperalgesia and neurophysio-
logical alterations in nerve function, whereas many patients also report other symptoms such
as numbness, tingling and ongoing pain.
Theoretically it would be better to use animal models that replicate all symptoms observed
in humans. This remains however until today very challenging. Measures like numbness, tin-
gling and ongoing pain rely on verbal report from the patient, often occur spontaneously, and
therefore are very difficult to replicate in animal models. Fortunately, investigation into novel
measures of ongoing pain in rodents is an emerging are, but for now, developing animal mod-
els of CIPN which replicate all the symptoms that patients report remains very challenging,
and we therefore focus in this review on allodynia/ hyperalgesia and neurophysiological alter-
ations in nerve function.
Second, the internal validity of the included studies could not be reliably estimated as many
of the essential methodological details of animal studies included in our review were poorly
reported. 44% and respectively 35% of the included studies reported any measure for blinding
or randomization, and only 3% reported sample size calculation or power analyses validating
the group sizes that they used.
As a consequence, we cannot reliably estimate how valid the results of the included studies
are. Nevertheless, we included the poorly reported papers in this review because papers that do
not report essential details are not necessarily methodologically impaired. However, it is
important to emphasize that consistent reporting of essential details regarding experimental
design for future animal experiments, as described for example in the ARRIVE guidelines, is
urgently needed.
Third, our relative low reproducibility number (n = 5) in combination with high efficacy
levels (at least 90% in 2 patient important outcomes) may have led to potentially excluding rel-
evant CIPN models. We therefore created a list containing all models that were excluded from
analyses because they did not reach our reproducibility limit (n = 5). In addition, we con-
ducted a sensitivity analyses in which we challenged our efficacy level and showed that in case
the efficacy level was reduced to 85% the same three effective models using an administration
route used in clinical practice are identified, and one other promising model enters the scene
(e.g. mice C57BL/6, male, receiving paclitaxel). This new model provides us with additional
evidence that all mice models using paclitaxel using an administration route used in clinical
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practice seem effective (as only the sex is different in this new model compared to one of our
previous identified effective models using an administration route in clinical practice).
Fourthly, our conclusions are based on vote counting (is there any evidence of CIPN, or in
other words; comparing the number of studies with a significant effect to the number of stud-
ies with a non-significant outcome), and the significance of the effect as calculated by the
author. This approach has some limitations as we needed to trust that the authors used appro-
priate statistical tests and that in vote counting procedures the weight of the individual study
(largely based on the sample size) is not taken into account.
We nevertheless believe that pooling our results (conducting a real meta-analysis) is not
sensible in this case, as we are not interested in an overall summary effect nor the actual effect
size, but only the significance of the individual effects.
Fifthly, the studies included in this review are of course heterogenous on many more char-
acteristics than the four we included to define CIPN models (e.g. chemotherapy, species,
strain, sex). The dosage (actual amount, frequency and duration) of chemotherapy used may,
for example, have influenced whether a model was effective or not. We decided, however, not
to include dose as a component to assess the study for clinical relevance (step 3) because we
needed to make too many assumptions for each individual study regarding the representative
human patient group, the actual indication why the chemotherapeutics are prescribed, and
estimates to back transform human treatment regime to animal treatment regime, leading to
unreliable results.
In more detail; for each individual comparison the used animal population needs to be
matched to a human representative group (regarding, age, sex, weight etc). Subsequently for
each specific hypothetical human patients group, and each specific chemotherapeutic, a mini-
mal dose/ or treatment regime used in clinical practice needs to be determined. To do this,
many assumptions regarding the type of cancer and stage of disease need to be made (as vari-
ous types of cancer and stages of disease are treated with different treatment regimes, e.g. dose,
number of therapeutic cycles duration). Last but not least, the resulting theoretical dose/ treat-
ment regime needs to be back transformed to a relevant dose in the animal population using
estimates based on even more assumptions. In this paper we therefore did not include dose to
‘value” each individual animal model.
In addition, in our current analyses to determine reliable animal models for CIPN we focus
on efficacy, and all models that are selected did as a consequence score positive on our CIPN
related outcomes, and therefore the dosage used must have been sufficient.
Sixthly, although we included administration route as a component to assess the study for
clinical relevance and excluded in step 3 of our methodology all studies using routes of admin-
istration that are currently not recommended to use in clinical practice, there seems to be a
mismatch in the balance of administration routes used in our models compared to the clinical
situation. Paclitaxel and cisplatin, for example, are in our effective, robust CIPN models only
administered intravenously in the minority of papers (23% in C57BL/6 female mice receiving
paclitaxel, 8% in C57BL/6 male mice receiving cisplatin, and not at all in CD1 male mice
receiving paclitaxel) although in clinical practice these levels seem to be higher.
Another important issue regarding clinical relevance of the included models is that the
majority of animal models was cancer free, whereas in the clinical situation most CIPN patient
have or experienced previously cancer which may confound the results related to the used ani-
mal models
Last but not least there is a possibility that not all the studies investigating the efficacy of
CIPN models have been published. Potential CIPN models (varying in chemotherapy, dose,
administration route, species, strain, age etc.) that ultimately did not cause polyneuropathy
symptoms are probably not all published. This resulted in relatively high levels of efficacy of
Identifying effective, robust and relevant models for CIPN
PLOS ONE | https://doi.org/10.1371/journal.pone.0221787 August 28, 2019 12 / 17
the models included in this review. To partly overcome this, in our analyses we only selected
models as an effective model when they caused significant (peripheral) polyneuropathy in at
least 90% of the experiments.
Conclusions and future directions
In this systematic review we show evidence that mice CIPN models treated with either pacli-
taxel or cisplatin using an administration route used in clinical practice seem suitable models
to study CIPN. Three specific models using paclitaxel or cisplatin that stand out are 1) C57BL/
6 female mice receiving paclitaxel and 2) CD1 male mice receiving paclitaxel and 3) C57BL/6
male mice receiving cisplatin.
The results and comparisons between various CIPN models described in this paper can be
used by scientists that aim to select a suitable CIPN model for their research. We hypothesize
that by using effective and robust animal models that mimic the clinical situation as much as
possible, the translation to the clinical situation, with respect to the potential of identifying
promising treatments for CIPN in the future, will improve.
We believe that more research is needed in models that were potentially effective, but were
not reproduced enough to be included in this review, and that there is potential in studying
the differences in efficacy between CIPN models as this may help the research community to
unravel the mechanism behind the cause of CIPN
We further recommend that scientists in other research fields as well who are planning to
conduct animal experiments start with a transparent comparison of the available animal mod-
els. The methodology described in this paper can serve as a guidance document. In addition
we recommend that scientists register their trial (e.g. www.preclinicaltrials.eu) in order to
decrease the likelihood of publication bias [22] or at least publish their experiment according
to the available reporting and methodological quality guidelines [23, 24].
Materials and methods
This systematic review identifies animal models that investigate the effects of CIPN. The
review methodology was specified in advance and documented using SYRCLE’s systematic
review protocol for animal intervention studies [25] and put online on the SYRCLE Web site
(S2 File).
Literature search strategy
We performed a systematic, computerized search in Medline through the PubMed interface
and EMBASE to identify all the animal studies examining CIPN. The full search strategy (S3
File) was based on the search components “experimental animal” [25], “chemotherapy”, and
“polyneuropathy”. Search results from both databases were combined and duplicates were
removed. In addition, we checked the reference lists of all included studies and relevant
reviews identified by our search for additional eligible references. The search was performed
on May 18th, 2016 and updated on December 19th, 2017.
Study selection
All search results were imported in reference manager software. Abstract were initially
screened based on title and obvious irrelevant papers were excluded. Early Review Organising
Software (EROS; Institute of Clinical Effectiveness and Health Policy, Buenos Aires, Argen-
tina) was used to randomly allocate all remaining references to two independent reviewers,
who screened it for inclusion on the basis of its title and abstract (reviewers: SG, SW, SH, and
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ME). Studies were included if they met all of the following criteria: 1) the study was an original
full paper which presented unique data; 2) the study was performed in animals in vivo; 3) the
study examined the effect of chemotherapy; 4) the study reported on the outcome (peripheral)
neuropathy (e.g. mechanical allodynia, thermal hyper and hypoalgesia, sensory-motor coordi-
nation, electrophysiological measurements and/or histological damage to the peripheral ner-
vous system); 5) the study included an appropriate control group. No language or publication
date restrictions were applied. If necessary, publications in languages other than English were
translated by a native speaker for that particular language.
In case of doubt, the whole publication was evaluated. Full-text copies of all publications eli-
gible for inclusion were subsequently assessed by two independent reviewers and included
when they met our pre-specified inclusion criteria. Disagreement was solved by discussion or
by consulting a third investigator (CH).
Study characteristics and data extraction
We extracted bibliographic details such as author, journal, and year of publication, as well as
data on the following study characteristics: animal species, strain, sex, age, and weight; type of
chemotherapeutic used, dose, frequency, duration of treatment, and route of administration;
type of outcomes assessed (e.g. mechanical allodynia, thermal hyper and hypoalgesia, sensory-
motor coordination, electrophysiological measurements and/or histological damage to the
peripheral nervous system), method of outcome assessment and timing of the outcome mea-
surement relative to chemotherapy induced polyneuropathy induction.
With regard to outcome data extraction; we extracted for all relevant comparisons the pres-
ence of statistical evidence for a significant effect.
Methodological quality
The methodological quality of all selected studies was evaluated by scoring the reporting of
three key characteristics of scientific reporting: reporting of any measure of randomization,
reporting of any measure of blinding, and reporting of sample size and/or power calculation.
For these three items, a ‘Yes’ score indicates ‘reported’, and a ‘No’ score indicates ‘unreported’.
Data analyses
Step 1: All animal models were stratified according to the species, strain, sex, and type of che-
motherapy used. Efficacy of the animal models was assessed by analysing the number of times
the animal models was used in different papers, and the percentage of studies that showed a
significant effect of chemotherapy on (peripheral) polyneuropathy on either one or two of our
outcomes (e.g. mechanical allodynia, thermal hyper and hypoalgesia, sensory-motor coordina-
tion, electrophysiological measurements and/or histological damage to the peripheral nervous
system). Based on the results and conclusions of the authors of the original paper it was
decided whether the effect of chemotherapy induced (peripheral) polyneuropathy on our
selected outcomes was significant.
To be selected as models with promising efficacy, animal models needed to meet the follow-
ing criteria: 1) reproduced at least five times; 2) causing significant (peripheral) polyneuropa-
thy in at least 90% of the experiments in two or more outcomes. Subsequently (step 2), the
resulting list of promising animal models was assessed for robustness. The same analysis as
described above was repeated using different categories to define CIPN models. In our original
analyses CIPN models were classified based on species, strain, sex, and type of chemotherapy
used. In this robustness assessment CIPN models were classified according to either: 1) species
and chemotherapy alone; 2) species, strain, and chemotherapy; 3) species, chemotherapy, and
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sex, which allows us to assess how a model performs across strains and the sex of animals used.
In case a model performs well in all assessments it is to be expected that the model is quite
independent of the strain and sex of the animals used.
However, it is important to realize that the number of variations in models used within a
category and the amount of available evidence per model may influence the results of this
robustness assessment, and therefore the results of the robustness assessment will be analysed
with respect to the actual number of variations in models within each category (for example,
for a models to be considered as robust across sex, the animal model must have been tested in
both sexes, and in at least 2 different strains).
The above-mentioned analysis will lead to a list of models with the highest efficacy. How-
ever, in order to increase the utility of the list with the most promising animal models the ani-
mal model should mimic the clinical situation as closely as possible (step 3). Therefore, in a
subsequent analysis we excluded all models that used administration routes that were not used
in clinical practice (e.g. intraperitoneal vincristine and intradermal oxaliplatin) and repeated
our analysis as previously described. All analyses were compared.
Last but not least a sensitivity analyses was conducted. In our analyses a model could only
be selected as a promising and suitable model in case a model caused significant peripheral
neuropathy in at least 90% of the experiments in 2 or more outcomes. In the sensitivity analy-
ses we changed this level to 85% and re-analysed step 1 (efficacy), step 2 (robustness) and step
3 (mimicking the clinical situation).
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